Scott Sundick, MD
Vascular Surgery · Westfield, NJNPI 1649449687
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,055 of the $26,072 with a category attached, or 65.4%. 38 manufacturers reported payments, led by Penumbra, Inc. at 25.0% of the total. Reporting peaked in 2022 at $7,713 and has fallen 70.0% since, to $2,311 in 2025.
Across 587 payments — averaging $44.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$7K
- Medtronic$6K
- Bard Peripheral Vascular, Inc.$3K
- W. L. Gore & Associates, Inc.$2K
- Inari Medical, Inc.$1K
- Endologix LLC$1K
- plus $6K from 32 others
Across 10 payments — averaging $1040.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$10K
What the payments were for
- Consulting fees$2,50010%
- Speaking & faculty fees$4,80018%
- Travel & lodging$1,7187%
- Food & beverage$17,05565%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 48 | $6,507 |
| Medtronic(2 entities) | 351 | $6,089 |
| Bard Peripheral Vascular, Inc. | 9 | $3,161 |
| W. L. Gore & Associates, Inc. | 43 | $1,644 |
| Inari Medical, Inc. | 16 | $1,169 |
| Endologix LLC | 10 | $1,082 |
| Globus Medical | 2 | $908 |
| Mozarc Medical US LLC | 6 | $858 |
| Silk Road Medical, Inc. | 12 | $528 |
| Cardiovascular Systems Inc. | 9 | $506 |
| Cook Medical LLC | 3 | $369 |
| Bolton Medical Inc | 4 | $367 |
| Tactile Systems Technology Inc | 8 | $253 |
| Lemaitre Vascular, Inc. | 11 | $238 |
| Acera Surgical, Inc. | 4 | $236 |
| Angiodynamics, Inc. | 3 | $212 |
| Convatec Inc. | 4 | $209 |
| Smith+Nephew | 3 | $207 |
| Stryker | 5 | $185 |
| Limflow Inc. | 1 | $181 |
| Sanara Medtech Inc. | 1 | $150 |
| Shockwave Medical, Inc | 1 | $125 |
| Johnson & Johnson | 8 | $118 |
| EKOS Corporation | 1 | $107 |
| KCI USA, Inc. | 1 | $84 |
| Asahi Intecc USA, Inc. | 1 | $81 |
| Pfizer | 5 | $75 |
| Cvrx, Inc. | 1 | $75 |
| Lantheus Medical Imaging, Inc. | 3 | $72 |
| Abbott | 1 | $67 |
| Solventum Corporation | 2 | $43 |
| Boston Scientific | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Cashflow Solutions, LLC | 1 | $20 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $18 |
| Cordis US CORP. | 1 | $18 |
| Cagent Vascular Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUBY Coil$4,942
- Indigo System$947
- RISE$810
- Argyle$736
- GORE VIABAHN VBX Balloon Expandable Endo$706
- FLOWTRIEVER CATHETER, S$644
- CT THROMBECTOMY SYSTEM KIT$644
- Torus Stent Graft System$527
- ENDOCROSS Device$527
- HawkOne$408
- VIABAHN VBX Balloon Expandable Endoprosthesis$389
- Diamondback Peripheral$299
- Ovation$269
- FlowTriever$259
- ClotTriever$259
- IN.PACT Admiral$225
- SpiderFX$194
- LIMFLOW SYSTEM$181
- InnovaMatrix AC$158
- Grafts$154
How this compares
$26,072 in reported general payments places this provider in the 85th percentile of 182 vascular surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $30,240 |
| XareltoRivaroxaban | 23 | $14,779 |
| ClopidogrelClopidogrel Bisulfate | 52 | $894 |
| Cilostazol | 12 | $355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $30,24036 claims |
| Johnson & JohnsonXarelto | $118 | $14,77923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 vascular surgery providers in New Jersey.
Other vascular surgery in Westfield
- Andrew ChaWestfield$13K
- Salvador CuadraWestfield$12K
- Clifford SalesWestfield$11K
- Steven EliasEnglewood$509K
- Michael WildermanHackensack$383K
- David O'ConnorHackensack$272K
- Joseph LombardiPomona$266K
- William BeckermanNew Brunswick$176K
- Neil PoulsenRockaway$148K
- Massimo NapolitanoWayne$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.